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Abstract
To date no informative biomarkers exist to accurately predict presence of lymph node
metastases (LNM) in esophageal adenocarcinoma (EAC). We studied the discriminative
value of Olfactomedin 4 (OLFM4), an intestinal stem cell marker, in EAC. Patients who had
undergone esophagectomy as single treatment modality for both advanced (pT2-4) and
early (pT1b) adenocarcinoma of the esophagus or gastro-esophageal junction were
selected for this study from an institutional database (Erasmus MC University Medical Cen-
ter, Rotterdam, The Netherlands). Surgical resection specimens of 196 advanced and 44
early EAC were examined. OLFM4 expression was studied by immunohistochemistry and
categorized as low (<30%) or high (> = 30%) expression. Low OLFM4 was associated with
poor differentiation grade in both advanced (60% vs. 34.8%, p = 0.001) and early EAC
(39.1% vs. 9.5%, p = 0.023). LNM were present in 161 (82.1%) of advanced and 9 (20.5%)
of early EAC respectively. Low OLFM4 was independently associated with the presence of
LNM in advanced EAC in multivariable analysis (OR 2.7; 95% CI, 1.16–6.41; p = 0.022), but
not in early EAC (OR 2.1; 95% CI, 0.46–9.84; p = 0.338). However, the difference in associ-
ation with LNM between advanced (OR 2.7; 95% CI, 1.18–6.34; p = 0.019) and early (OR
2.3; 95% CI, 0.47–11.13; p = 0.302) EAC was non-significant (p = 0.844), suggesting that
the lack of significance in early EAC is due to the small number of patients in this group.
OLFM4 was not of significance for the disease free and overall survival. Overall, low expres-
sion of intestinal stem cell marker OLFM4 was associated with the presence of LNM. Our
study suggests that OLFM4 could be an informative marker with the potential to improve
preoperative assessment in patients with EAC. Further studies are needed to confirm the
value of OLFM4 as a biomarker for LNM.
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Introduction
Esophageal cancer is a common cancer with high incidence and mortality rate, with an esti-
mated 456 000 new cases and 400 000 deaths worldwide in 2012 [1], mostly due to diagnosis at
advanced incurable stages with limited treatment options. Different histologic types exist, with
esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) being the most fre-
quently encountered types. While ESCC incidences decline, EAC has been one of the fastest
rising malignancies in Western countries [2, 3]. Highest incidence rates per 100.0000 person-
years for EAC have been observed in the UK (7.2 in men, 2.5 in women) and the Netherlands
(7.1 in men and 2.8 in women) [3].
Metastases to the regional lymph nodes is the most important prognostic factor in EAC
patients undergoing treatment with curative intent [4–6]. Accurate pretreatment assessment
of nodal status is thus important for both advanced and early lesions. In early EAC, patients
eligible for endoscopic treatment only (i.e. not followed by surgical resection) should have a
minor risk of LNM, because of the inability to perform a lymphadenectomy during endoscopic
resection. However, despite all currently available clinical diagnostic modalities (especially
EUS, CT and PET) clinical assessment of nodal status is still suboptimal [7–9]. Therefore, a
more reliable tool is urgently needed in both advanced and early EAC.
Olfactomedin 4 (OLFM4, formerly known as hGC-1 or GW112) might be an interesting
candidate biomarker in this context. It is a secreted glycoprotein, originally identified as a gly-
coprotein expressed in the olfactory neuroepithelium of bullfrogs [10]. OLFM4 was first
cloned from human myeloblasts and is mainly expressed in the gastro-intestinal tract (stom-
ach, small intestine and colon), prostate and bone marrow [11]. In human colon crypts,
OLFM4 co-localizes with LGR5+ intestinal stem cells [12]. OLFM4 positive cells are also
found in gastric intestinal metaplasia and Barrett’s esophagus (BE), where it is confined to the
base of metaplastic glands, in a similar way as in colon crypts, with gradually increased expres-
sion during dysplastic progression [13]. OLFM4 is regulated by G-CSF [11], the transcription
factor NF-kappaB [14, 15], and the Wnt/β-catenin pathway [16] and can mediate cell adhesion
through its interactions with extracellular matrix proteins such as cadherins and lectins [17].
In gastric cancer, low OLFM4 expression is correlated with poor differentiation grade and
the presence of LNM, as well as with adverse survival [18–21]. Similarly, decreasing frequen-
cies of expression along with cancer progression have been found in breast, endometrial, pros-
tate and colon carcinoma amongst others [22–25]. Because no data on OLFM4 in EAC are
available yet, this study was undertaken to investigate the association between OLFM4 and
presence of LNM and prognosis in both advanced and early EAC. We hypothesized low
OLFM4 expression in EAC is associated with the presence of LNM and could be a potential
biomarker for stratification of patient treatment.
Materials & methods
Patients’ selection & study design
Patients who underwent esophagectomy with curative intent for pathologically confirmed
pT2-pT4 adenocarcinoma of the esophagus or gastro-esophageal junction between 1995 and
2016 in the Erasmus MC University Medical Center, Rotterdam were selected for this study.
Patients were identified from a prospectively collected institutional database. To assure accu-
rate pathological LNM status, patients treated with surgical resection and at least 12 lymph
nodes in the resection specimen were included. Patients with concurrent cancer(s) in other
organs and/or those dying from surgical complications (survival < 1 month) were excluded as
well as patients that received (neo-) adjuvant chemoradiation therapy ((n)CRT). In addition,
OLFM4 and metastases in esophageal adenocarcinoma
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all patients with early (pT1b) EAC, treated between 1992–2014 at the Erasmus MC, were inves-
tigated. These patients were treated by either primary esophagectomy or endoscopic resection
followed by esophagectomy because of poor prognostic criteria found in the endoscopic resec-
tion specimen. To increase patient numbers in the early EAC group, patients with early EAC
and less than 12 pathologically examined lymph nodes, but available follow-up for more than
60 months were also included.
Clinical and pathological data had been prospectively collected, including age at surgery,
sex, tumor location and size, surgical technique, resection margin status, differentiation grade,
presence (pN-/ pN+) and number (pN0-3) of pathologically confirmed lymph node metastasis
and disease free survival (DFS) and overall survival (OS). Resection margin positivity was
defined as presence of tumor cells in the (inked) resection margin (definitions according to
the College of American Pathologists (CAP)) [26]. Recurrence was defined as either locoregio-
nal or distant during follow-up, which was either a clinical diagnosis and sometimes patholog-
ically confirmed. DFS was defined as time between the date of surgery and first occurrence of
disease progression. OS was defined as time between surgery and death. Patients lost to follow-
up were censored at the time of the last visit to the outpatient clinics. The TNM system accord-
ing to the UICC seventh edition was used for pathological grading and staging [4]. However,
corresponding to the eighth edition, which shows no changes in the definitions of the T, N,
and M categories, only carcinomas with their epicentre within the proximal 2 cm of the cardia
(Siewert types I and II tumors) were included [27].
Specimen characteristics
The hematoxylin-eosin stained slides and tissue blocks were retrieved from the archives of the
Department of Pathology at the Erasmus MC University Medical Center and re-assessed for
tumor staging, grading and additional immunohistochemical staining (IHC) for OLFM4.
From the most representative slide with deepest tumor invasion, the FFPE block was selected
and 4 μm thick sections were cut from this block. OLFM4 (clone DIE4M, Cell Signalling ref.
14369) staining was performed using an automated immunostainer (BenchMark Ultra, Ven-
tana Medical Systems, Roche, Tuscon, AZ, USA). In brief, deparaffinization according to
BenchMark Ultra protocol and antigen retrieval by CC1 antigen retrieval solution (64 min, ref.
950–124, Ventana Medical Systems) were performed. Tissues were incubated with the primary
antibody OLFM4 (32 min, dilution 1:400). Detection was performed with UltraView-DAB
(ref. 760–500, Ventana Medical Systems) and amplification with Amplification Kit (ref. 760–
080 Ventana Medical Systems). Next, the slides were counterstained with hematoxylin (ref:
790–2208, Ventana Medical Systems) and coverslipped. Each slide contained normal colon tis-
sue as a positive control. Furthermore, normal tissue surrounding the tumor was evaluated for
its physiological expression of OLFM4 and to assess background staining. OLFM4 expression
was scored based on the percentage of tumor cells with cytoplasmic OLFM4 staining. In addi-
tion, the H-score based on predominant staining intensity (no / weak/ moderate/ strong stain-
ing) was initially scored in a discovery set (n = 57). When present in the same slide (adjacent
to tumor) OLFM4 expression was also evaluated in non-dysplastic Barrett’s esophagus
(NDBE). Barrett’s esophagus was defined by metaplasia of the pre-existent squamous epithe-
lium into columnar epithelium containing goblet cells[28]. All OLFM4 stained slides were
reviewed independently by two investigators (LS and FK), blinded to the clinical and patholog-
ical outcome. In case of disagreement, a consensus was reached by review by both investiga-
tors. Specifically, 126 out of 240 cases showed a relatively small difference (1–10%) in scoring,
of which the numbers were averaged. In 32 cases a difference of more than 10% was found,
and a consensus was reached in a consensus meeting.
OLFM4 and metastases in esophageal adenocarcinoma
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Statistical analysis
The optimal cut-off value of OLFM4 expression was based on receiver operating characteristic
(ROC) curve analysis in advanced EAC, and corresponding Youden index (S1 Fig). Based on
this evaluation, low OLFM4 was defined as< 30% expression, otherwise OLFM4 was consid-
ered to be high. The interobserver variation for the assessment of OLFM4 staining between the
two observers was calculated using the intraclass correlation coefficient. Strength of agreement
was categorized as follows: 0.00–0.20, poor; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80,
good; and 0.81–1.00, excellent.
Required sample size was not calculated a priori as no pilot data on OLFM4 in EAC was
available to determine an expected effect size and it was also predetermined by study con-
straints. Differences between the advanced and early EAC cohorts were analyzed using Stu-
dent’s t test for normal distributions and the Mann–Whitney U test for non-normal
distributions of continuous variables, and Pearson’s chi-squared (χ2) test for categorical vari-
ables. Normality of distributions were assessed using the Shapiro-Wilk Test of Normality and
by looking at the histogram plot. Correlations between clinicopathological variables and
OLFM4 expression were analysed using χ2- test or Fisher’s exact test. Multivariable logistic
regression was used to calculate independent associated factors for LNM in the resection speci-
men (pN+). Only variables that were statistically significant in univariable analysis were
included in multivariable analysis. To investigate whether the association of OLFM4 was dif-
ferent in advanced and early EAC we performed a logistic regression analysis containing all
relevant confounders, OLFM4 status, early or advanced EAC and the interaction between
OLFM4 status and early or advanced EAC.
Kaplan Meier curves were used to plot the 5-year DFS and OS by OLFM4 status and the
distribution was analyzed using the log-rank test. Uni- and multivariable Cox proportional
hazard models were applied to calculate the association between OLFM4 and survival. In mul-
tivariable analysis all clinical and pathological factors which proved to be prognostic for sur-
vival in univariable analysis were included (p<0.05). Statistical analysis was performed using
SPSS-software (version 22, SPSS IBM inc, Armonk, NY, USA). A p-value of<0.05 (two-sided)
was considered statistically significant. This study was reported according to the Reporting
recommendations for tumor marker prognostic studies (REMARK, S1 Table) [29].
Ethical approval
This study was approved by the institutional review board (medical ethical committee) from
the Erasmus Medical Center (Rotterdam, The Netherlands).
Results
Patient characteristics
A diagram depicting the flow of patients throughout the study is shown in Fig 1. Out of 240
EAC patients investigated in this study, 196 had advanced EAC (pT2-4) and 44 early EAC
(pT1b). Clinicopathological characteristics are listed in Table 1.
Pattern of OLFM4 expression
In total, 240 EAC resection specimens were assessed for OLFM4 expression. The interobserver
agreement for OLFM4 assessment was “good” to “excellent” between the two observers with
an intraclass correlation co-efficient of 0.871 (95% CI, 0.782–0.918). However, the H-score
resulted in a poor interobserver agreement (Cohen’s kappa 0.2) and was disregarded from fur-
ther analysis. In normal esophageal tissue (without presence of Barrett’s esophagus), OLFM4
OLFM4 and metastases in esophageal adenocarcinoma
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expression was absent (S2 Fig). In total, 87 (36.2%) EACs showed high OLFM4 expression and
153 (63.8%) EACs showed low OLFM4 expression (Fig 2). Mostly, expression of OLFM4 was
homogeneous, but occasionally, heterogeneous OLFM4 expression was observed, with pre-
dominantly high OLFM4 expression towards the lumen and absence of OLFM4 expression
towards the invasive front (S3 Fig). Non-dysplastic Barrett’s esophagus (NDBE) showed a sim-
ilar staining pattern as normal human colon, with cytoplasmic OLFM4 expression in the crypt
basis (Fig 2). As in NDBE, OLFM4 expression was noted in the cytoplasm of the EAC cells
(Fig 2C).
OLFM4 expression and clinico-pathological characteristics in advanced
and early EAC
In advanced EAC, 78 out of 130 (60%) cases with low OLFM4 expression were poorly differen-
tiated, compared to 23 out of 66 (34.8%) EAC with high expression (p = <0.001, Table 2). A
similar association between differentiation grade and OLFM4 expression was found in early
EAC (9/23 (39%) vs. 2/21 (10%), p = 0.023). Low OLFM4 expression was also associated with
presence of pathologically confirmed LNM at the time of resection in EAC (119/153 (78%) vs
51/87 (59%), p = 0.002). In advanced EAC OLFM4 was associated with LNM (113/130 (87%)
vs 48/66 (73%), p = 0.014), but not in early EAC (6/23 (26%) vs 3/21 (14%), p = 0.332).
To identify the odds ratio (OR) of clinicopathological characteristics for presence of LNM
in EAC, uni- and multivariable logistic regression analysis were performed (Table 3). In multi-
variable analysis, positive resection margin (OR 7.8, 95% CI, 1.70–35.68, p = 0.008), higher
Fig 1. Flow diagram depicting the flow of patients throughout the study. EAC, esophageal adenocarcinoma; nCRT, neo-adjuvant chemo-radiation
therapy; OS, overall survival; FU, follow-up, LN, lymph nodes; OLFM4, Olfactomedin 4; IHC, immunohistochemistry.
https://doi.org/10.1371/journal.pone.0219494.g001
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Table 1. Patient characteristics�.
All patients
(Advanced + Early),
Advanced EAC (pT2-4), Early EAC
(pT1b),
Advanced vs Early
n = 240 n = 196 n = 44 p-value�
Age, years (mean [SD]) 63 (10) 63 (10) 62 (9) 0.445§
Sex (n[%]) Male 199 (82.9) 165 (84.2) 34 (77.3) 0.271
Female 41 (17.1) 31 (15.8) 10 (22.7)
Surgery (n[%]) Transhiatal 150 (62.5) 120 (61.2) 30 (68.2) <0.001
Transthoracal 69 (28.8) 67 (34.2) 2 (4.5)
Total/Partial Gastric 9 (3.7) 8 (4.1) 1 (2.3)
Unknown 12 (5.0) 1 (0.5) 11 (25)
Siewert classification,¥(n[%])
Type 1 114 (47.5) 80 (40.8) 34 (77.3) <0.001
Type 2 125 (52.1) 116 (59.2) 9 (20.5)
Tumor size, mm▼ (mean [SD]) 46.6 (24.2) 50.6 (23.8) 27.4 (15.8) <0.001§
Radicality (n[%]) R0 179 (74.6) 135 (68.9) 44 (100) <0.001
R1 61 (25.4) 61 (31.1) 0 (0)
Grade (n[%]) Well / Moderate 128 (53.3) 95 (48.5) 33 (75) 0.001
Poor 112 (46.7) 101 (51.5) 11 (25)
pT (n[%]) pT1b 44 (18.3) 0 (0) 44 (100) <0.001
pT2 25 (10.4) 25 (12.8) 0 (0)
pT3 168 (70.0) 168 (85.7) 0 (0)
pT4 3 (1.3) 3 (1.5) 0 (0)
pN (n[%]) pN0 70 (29.2) 35 (17.9) 35 (79.5) <0.001
pN1 49 (20.4) 44 (22.4) 5 (11.4)
pN2 54 (22.5) 51 (26.0) 3 (6.8)
pN3 67 (27.9) 66 (33.7) 1 (2.3)
pN- / pN+ (n[%]) pN- 70 (29.2) 35 (17.9) 35 (79.5) <0.001
pN+ 170 (70.8) 161(82.1) 9 (20.5)
Total LN (median [IQR]) 18 (14–26) 19 (15–27) 14 (8–17) <0.001˚
LNM (median [IQR] 3 (0–7) 4 (1–8) 0 (0–0) <0.001˚
Recurrence,¶ n[%]) No 98 (40.8) 66 (33.7) 32 (72.7) <0.001
Yes 140 (58.3) 130 (66.3) 10 (22.7)
Locoregional recurrence,¥ (n[%])
No 163 (67.9) 123 (62.8) 40 (90.9) <0.001
Yes 76 (31.7) 73 (37.2) 3 (6.8)
Distant recurrence,¶ (n[%]) No 126 (52.5) 94 (48.0) 32 (72.7) <0.001
Yes 112 (46.7) 102 (52.0) 10 (22.7)
pN+ and/ or recurrence,¥ (n[%])
No 49 (20.4) 22 (11.2) 27 (61.4) <0.001
Yes 190 (79.2) 174 (88.8) 16 (36.4)
60 months survival (n[%]) Alive 79 (32.9) 46 (23.5) 33 (75.0) <0.001
Deceased 161 (67.1) 150 (76.5) 11 (25.0)
Follow-up time, months (median [IQR] 25 (9–64) 19 (8–48) 38 (47–80) <0.001˚
DFS, months (median [IQR]) 17 (7–60) 13 (6–35) 63 (32–77) <0.001˚
OS, months (median [IQR]) 25 (9–64) 19 (8–48) 64 (47–80) <0.001˚
OLFM4 expression,1 (n[%]) Low 153 (63.8) 130 (66.3) 23 (59.0) 0.080
(Continued)
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pT-stage (pT34, OR 4.0; 95% CI, 1.53–10.29, p = 0.005) and low OLFM4 expression (OR 2.7;
95% CI, 1.16–6.41; p = 0.022) were identified as independent prognostic variables for LNM in
advanced EAC. In contrast, no independently prognostic variables were found in early EAC.
However, in the combined cohort the interaction test showed no significant difference in
strength of the association of OLFM4 with LNM in advanced (OR 2.7.; 95% CI, 1.18–6.34;
p = 0.019) and early (OR 2.3; 95% CI, 0.47–11.13; p = 0.302) EAC (p = 0.844, Table 4). In other
words, this test shows that there is no reason to assume that the association between OLFM4
and presence of LNM is different between both groups.
Table 1. (Continued)
All patients
(Advanced + Early),
Advanced EAC (pT2-4), Early EAC
(pT1b),
Advanced vs Early
n = 240 n = 196 n = 44 p-value�
High 87 (36.2) 66 (33.7) 21 (41.0)
�P-values were based on Pearson’s chi-squared test, unless indicated otherwise. All statistical tests were two-sided. SD, standard deviation; R1, positive; R0, negative
resection margins; IQR, interquartile range.
§ P-values were based on Student’s t-test.
˚ P-values were based on Mann-Whitney test.
¥ One sample (early EAC) had unknown data.
▼Eight samples (4 advanced, 4 early EAC) had unknown data.
¶ Two samples (early EAC) had unknown data.
1 Low OLFM4 < 30% and high OLFM4�30% immunohistochemical expression.
https://doi.org/10.1371/journal.pone.0219494.t001
Fig 2. Examples of OLFM4 expression. OLFM4 expression in A, B) normal human colon tissue and C, D) non-dysplastic Barrett’s esophagus
overlying OLFM4 negative tumor cells (divided by dotted line). Representative cases of esophageal adenocarcinoma with E, F) high and G, H)
low OLFM4 expression (A, C, E, G: hematoxylin- eosin; B, D, F, H: OLFM4).
https://doi.org/10.1371/journal.pone.0219494.g002
OLFM4 and metastases in esophageal adenocarcinoma
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OLFM4 expression and prognosis
DFS was significantly better in patients with high OLFM4 expression (for advanced and early
EAC cohorts combined, log-rank test, p = 0.024). This was confirmed by univariable COX
regression analysis (HR 1.5; 95% CI, 1.05–2.15, p = 0.027). However, this observation did not
hold in multivariable analysis (S2 Table). There was no significant difference in OS between
EAC with low vs. high OLFM4 expression. Hence, OLFM4 expression was not prognostic for
OS (S3 Table). Kaplan-Meier curves for both DFS and OS according to OLFM4 expression are
depicted in S4 Fig.
Table 2. Distribution of OLFM4 expression according to clinicopathological characteristics in advanced and early EAC.
All patients (Advanced
+ Early), n = 240
Advanced EAC (pT2-4),
n = 196
Early EAC (pT1b),
n = 44
Low
n (%)
High
n (%)
p-value� Low
n (%)
High
n (%)
p-value� Low
n (%)
High
n (%)
p-value�
Age <65 81 (52.9) 46 (52.9) 0.992 68 (52.3) 34 (51.5) 0.916 13 (56.5) 12 (57.1) 0.967
> = 65 72 (47.1) 41 (47.1) 62 (47.7) 32 (48.5) 10 (43.5) 9 (42.9)
Sex Male 129 (84) 70 (80.5) 0.446 111 (85.4) 54 (81.8) 0.518 18 (78.3) 16 (76.2) 0.870
Female 24 (15.7) 17 (19.5) 19 (14.6) 12 (18.2) 5 (21.7) 5 (23.8)
Surgery Transhiatal 93 (60.8) 57 (65.5) 0.467 76 (58.5) 44 (66.7) 0.265 17 (73.9) 13 (61.9) 0.393
Other 60 (39.2) 30 (34.5) 54 (41.5) 22 (33.3) 6 (26.1) 8 (38.1)
Siewert Classification, ¥,
Type 1 75 (49.3) 39 (44.8) 0.501 57 (43.8) 23 (34.8) 0.226 18 (81.8) 16 (76.2) 0.650
Type 2 77 (50.7) 48 (55.2) 73 (56.2) 43 (65.2) 4 (18.2) 5 (23.8)
Tumor Size, ▼ <5 cm 85 (57.4) 44 (52.4) 0.457 66 (52.0) 28 (43.1) 0.243 19 (90.5) 16 (84.2) 0.550
> = 5 cm 63 (42.6) 40 (47.6) 61 (48.0) 37 (56.9) 2 (9.5) 3 (15.8)
Radicality R0 115 (75) 64 (73.6) 0.784 92 (70.8) 43 (65.2) 0.422 23 (100) 21 (100) NA
R1 38 (24.8) 23 (26.4) 38 (29.2) 23 (34.8) 0 (0) 0 (0)
Grade Well/ moderate 66 (43.1) 62 (71.3) <0.001 52 (40.0) 43 (65.2) 0.001 14 (60.9) 19 (90.5) 0.023
Poor 87 (56.9) 25 (28.7) 78 (60.0) 23 (34.8) 9 (39.1) 2 (9.5)
pT pT12 38 (24.8) 31 (35.6) 0.076 15 (11.5) 10 (15.2) 0.474 23 (100) 21 (100) NA
pT34 115 (75) 56 (64.4) 115 (88.5) 56 (84.8) 0 (0) 0 (0)
pN pN0 34 (22.2) 36 (41.4) 0.008 17 (13.1) 18 (27.3) 0.040 17 (73.9) 18 (85.7) 0.380
pN1 33 (21.6) 16 (18.4) 29 (22.3) 15 (22.7) 4 (17.4) 1 (4.8)
pN2 42 (27.5) 12 (13.8) 40 (30.8) 11 (16.7) 2 (8.7) 1 (4.8)
pN3 44 (28.8) 23 (26.4) 44 (33.8) 22 (33.3) 0 (0) 1 (4.8)
pN- / pN+ pN- 34 (22.2) 36 (41.4) 0.002 17 (13.1) 18 (27.3) 0.014 17 (73.9) 18 (85.7) 0.332
pN+ 119 (78) 51 (58.6) 113 (86.9) 48 (72.7) 6 (26.1) 3 (14.3)
Recurrence (loco- regional or distant), ¶
No 54 (35.8) 44 (50.6) 0.025 39 (30.0) 27 (40.9) 0.127 15 (71.4) 17 (81.0) 0.469
Yes 97 (64.2) 43 (49.4) 91 (70.0) 39 (59.1) 6 (28.6) 4 (19.0)
pN+ and/ or Recurrence, ¥
No 22 (14.5) 27 (31.0) 0.002 10 (7.7) 12 (18.2) 0.028 12 (54.5) 15 (71.4) 0.252
Yes 130 (85.5) 60 (69.0) 120 (92.3) 54 (81.8) 10 (45.5) 6 (28.6)
�Pearson’s chi-squared test. NA, not applicable, because all patients with early EAC had negative resection margins (R0) and were per definition staged pT1.
¥ One sample (early EAC) had unknown data.
▼Eight samples (4 advanced, 4 early EAC) had unknown data
¶ Two samples (early EAC) had unknown data.
https://doi.org/10.1371/journal.pone.0219494.t002
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Discussion
This is the first extensive study on OLFM4, an intestinal stem cell marker, in EAC and shows
low OLFM4 expression is associated with positive LNM status. Accurate pretreatment staging
of patients with early and advanced EAC is important for optimal treatment selection and sur-
vival prediction [4–6]. Previous studies have shown that pretreatment staging is frequently
inaccurate in EAC [9, 30–33]. In a recent publication on nCRT-naïve patients with standard
pre-operative assessment only 35% of patients were preoperatively diagnosed with a correct T-
and N-stage [34]. Particularly in patients with early (pT1) EAC, prevalence of LNM is highly
variable and to date unpredictable, while positive LNM status is highly predictive for a poor
5-year survival [30, 35].
Table 3. Logistic regression analysis to evaluate the independent association of OLFM4 with LNM (pN+)�.
All patients
(Advanced + Early EAC, n = 240)
Advanced EAC
(pT2-4, n = 196)
Early EAC
(pT1b, n = 44)
Univariable Multivariable Univariable Multivariable Univariable
OR
(95% CI)
p-value OR
(95% CI)
p-value OR
(95% CI)
p-value OR
(95% CI)
p-value OR
(95% CI)
p-value
Age
> = 65 (<65 = ref.) 1.1
(0.62–1.89)
0.785 1.0
(0.47–2.02)
0.936 1.1
(0.24–4.66)
0.932
Sex
Male (Female = ref.) 1.3
(0.64–2.71)
0.442 1.1
(0.42–3.00)
0.813 1.0
(0.18–6.02)
0.968
Surgery
Other (Transhiatal = ref.) 1.0
(0.58–1.82)
0.942 0.9
(0.45–1.98)
0.870 0.5
(0.10–3.06)
0.492
Siewert Classification, ¥
Type 2 (Type 1 = ref.) 1.9
(1.10–3.44)
0.022 0.9
(0.44–2.01)
0.867 1.0
(0.46–2.02)
0.914 1.1
(0.19–6.52)
0.915
Tumor Size, ▼
> = 5 cm (<5 cm = ref.) 2.5
(1.33–4.53)
0.004 1.9
(0.90–4.00)
0.095 1.2
(0.58–2.55)
0.609 2.7
(0.37–19.15)
0.330
Radicality
R1 (R0 = ref.) 18
(4.28–76.37)
<0.001 8.3
(1.83–37.76)
0.006 9.5
(2.21–41.21)
0.003 7.8
(1.70–35.68)
0.008 NA
Grade
Poor (Well/ moderate = ref.) 2.7
(1.49–4.87)
0.001 1.1
(0.50–2.37)
0.841 2.4
(1.10–5.09)
0.027 1.2
(0.48–2.78)
0.751 0.8
(0.14–4.73)
0.829
pT
pT34 (pT12 = ref.) 14
(7.03–26.87)
<0.001 7.2
(3.27–15.80)
<0.001 5.9
(2.42–14.60)
<0.001 4.0
(1.53–10.29)
0.005 NA
OLFM4 expression
Low (High = ref.) 2.5
(1.39–4.38)
0.002 2.6
(1.22–5.62)
0.013 2.5
(1.19–5.25)
0.016 2.7
(1.16–6.41)
0.022 2.1
(0.46–9.84)
0.338
� Uni- and multivariable logistic regression analysis was performed to investigate the independent association between LNM and clinicopathological characteristics,
only variables significant in univariable analysis were included in multivariable analysis. Hence, no multivariable analysis for early esophageal adenocarcinoma (EAC)
was performed. OR, odds ratio; CI, confidence interval; ref., reference; NA = not applicable, because all patients with early EAC had negative resection margins (R0) and
were per definition staged pT1.
¥ One sample (early EAC) had unknown data.
▼Eight samples (4 advanced, 4 early EAC) had unknown data.
https://doi.org/10.1371/journal.pone.0219494.t003
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The significance of OLFM4 in cancer is still controversial. OLFM4 is able to interact with
cell surface proteins and known to facilitate cell-cell adhesion [17, 36]. OLFM4 has been attrib-
uted oncogenic properties as it was shown to promote tumor growth by acting as an anti-apo-
ptotic protein and by increasing the mitotic activity of cancer cells [37, 38]. On the other hand,
reduced OLFM4 expression was significantly associated with poor prognosis in patients with
gastric [20], colorectal [23, 39] and breast carcinoma [24] amongst others. In gastric carcinoma
OLFM4 was also associated with metastasis [20, 21].
The present study shows low OLFM4 expression was associated with poorly differentiated
EAC, this is in concordance with the literature. In fact, in most cancers, a strong association
between low OLFM4 and poor tumor differentiation grade was found, including gastric,
colon, ovarian and prostate cancer [17, 18, 21, 22, 27, 28]. These findings suggest tumor sup-
pressive properties of OLFM4 and are in line with results found in various functional studies
[16, 40, 41]. For example, in gastric cancer cell lines OLFM4 had an inhibitory effect on cell
invasion via regulation of focal adhesion kinase (FAK) signaling [41].
Furthermore, low OLFM4 expression, but not poor tumor differentiation, was indepen-
dently associated with LNM in advanced EAC in the present study. Because LNM status is crit-
ical for the choice of treatment in early EAC, the investigation was extended to early EAC and
44 patients with pT1b tumors were separately analyzed. The overall incidence of LNM in the
pT1b group (20.5%) was in line with previous reports [29, 30]. Similar as in advanced EAC,
loss of OLFM4 was associated with poor differentiation grade, but no association with LNM
status was found. However, the interaction test in the combined cohort showed no significant
difference in strength of the association of OLFM4 and LNM between the advanced and early
Table 4. Multivariable logistic regression analysis to evaluate the association of OLFM4 with LNM (pN+) in all patients (left) with corresponding interaction model
(right)�.
OR p-value OR p-value
Siewert Classification, ¥ Type 2
(Type 1 = ref.)
1.0
(0.48–2.11)
0.992 1.0
(0.48–2.11)
0.992
Tumor Size, ▼ > = 5 cm
(<5 cm = ref.)
1.6
(0.76–3.37)
0.217 1.6
(0.76–3.37)
0.217
Radicality R1
(R0 = ref.)
10.4
(2.32–46.73)
0.002 10.5
(2.33–47.20)
0.002
Grade Poor (Well/ moderate = ref.) 1.1
(0.52–2.44)
0.762 1.1
(0.52–2.44)
0.767
pT pT234 (pT1 = ref.) 8.2
(3.17–21.12)
<0.0001 7.3
(1.75–30.77)
0.007
OLFM4 expression Low (High = ref)
Early EAC, n = 44 pT1 2.3
(0.47–11.13)
0.302
Advanced EAC, n = 196 pT234 2.7
(1.18–6.34)
0.019
All patients, n = 240 pT1234 2.6
(1.24–5.62)
0.012
Interaction§ (Early vs Advanced) 1.2
(0.21–6.91)
0.844
� Only variables significant in univariable analysis were included in multivariable analysis. OR, odds ratio; ref., reference; R1, positive; R0, negative resection margins
¥ One sample (early EAC) had unknown data.
▼Eight samples (4 advanced, 4 early EAC) had unknown data.
§ The interaction variable indicates whether there is a difference in association of OLFM4 with LNM between early and advanced EAC. The model with separate effects
of OLFM4 for early and advanced EAC did not give a better fit than the model with one effect only.
https://doi.org/10.1371/journal.pone.0219494.t004
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EAC. Therefore, the result in the early EAC might be explained by the small sample size and
overall low LNM incidence in this group of patients. Only one previous study studied the role
of OLFM4 in early cancer (pT1a and pT1b gastric cancer, n = 105) and concluded that low
OLFM4 expression was independently predictive for LNM [21].
Despite the association with LNM, in contrast with results found in other types of cancer,
OLFM4 seems to have no effect on clinical outcome. However, there are some important dif-
ferences between the present study and the aforementioned previous studies on OLFM4 in
other cancers. In the present study, only patients with at least 12 lymph nodes resected and
identified were included, in order to reduce the percentage of patients with falsely negative
pN0 [42]. Although others may have included more cases, these studies were frequently based
on patients with various tumor stages and mostly used tissue micro-arrays (TMAs) instead of
whole tissue slides. In addition, different methods for scoring OLFM4 IHC were applied mak-
ing comparison of results difficult [18–23]. Importantly, TMAs may not accurately demon-
strate tumor heterogeneity, which was observed in our study occasionally. In addition, whole
tissue slides allow for simultaneous analyses of adjacent non-tumorous tissue and Barrett’s
esophagus. It would be very interesting to investigate OLFM4 expression in low-grade and
high-grade dysplasia. However, in our samples, BE, with or without dysplasia, was present in
only a limited number of cases. Therefore, investigation of OLFM4 expression patterns during
neoplastic progression would require a separate study design using well defined sample
criteria.
There are also some limitations to the present study. Specifically, all patients were from one
academic center. Also, patients were treated with surgery alone, while current guidelines rec-
ommend nCRT prior to surgery for advanced EAC. However, additional treatment prior to
surgery might influence OLFM4 expression and survival, hence it was decided to use a nCRT-
naïve patient cohort.
In conclusion, the present study shows that low OLFM4 expression was independently
associated with LNM in EAC and hence might prove useful as a new biomarker. Improved
prediction of LNM presence could benefit decision making in treatment of EAC patients. This
is particularly important in early EAC where overtreatment can be avoided by endoscopic sub-
mucosal resection. More research is required to investigate whether OLFM4 is indeed biologi-
cally and clinically relevant in both advanced and early EAC.
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